FDA Clearance Tracker · P190023-S029
Navitor TAVI System with Vision Technology
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 3, 2026
Approved
Time to decision
180 days
Received Dec 5, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P190023-S029
- Device name
- Navitor TAVI System with Vision Technology
- Applicant
- ABBOTT MEDICAL
- Applicant location
- St. Paul, MN
- Received
- Dec 5, 2025
- Decided
- Jun 3, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Labeling Change - PAS
- Original approval
- P190023
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
approval for modifications to the Instructions for Use to reflect the 5-year findings of the Post-Approval Study (PAS) Report submitted for the long term follow-up of the Portico TAVI System prospective cohort study
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.